A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.
Epistemonikos ID: 9ce5f7432e051a77591e660143f2c9f31461dc22
First added on: May 10, 2024